Celltrion USA, a United States subsidiary of South Korean biopharmaceutical company Celltrion, announced on Sunday that it has submitted a Biologics License Application (BLA) for CT-P39, an interchangeable biosimilar candidate to XOLAIR (omalizumab) to the US Food and Drug Administration (FDA).
The BLA submission includes results from a global Phase III clinical trial designed to evaluate the efficacy, safety, and pharmacokinetics of CT-P39 compared to the reference product XOLAIR in patients with chronic spontaneous urticaria (CSU) up to Week 40. In November 2023, the company revealed the primary results of its 12-week clinical trial during the American College of Allergy, Asthma and Immunology (ACAAI) conference in Anaheim, California.
The Celltrion USA application for CT-P39 includes all the indications for which XOLAIR, an injectable biologic medicine, is approved, including asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), IgE-mediated food allergy (US only) and CSU.
Thomas Nusbickel, Celltrion USA chief commercial officer, said, 'We are pleased with the rapid progress made in the development of CT-P39, and we look forward to expanding our portfolio beyond immunology and oncology. We will continue to build upon our strong track record of developing and manufacturing high-quality biosimilars to help improve the lives of patients.'
Celltrion USA submits CT-P39 Biologics License Application to FDA
Ionis Pharmaceuticals names new executive vice president, chief global product strategy officer
Allergy Therapeutics reports positive G306 Phase III trial results for Grass MATA MPL
NeoImmuneTech's NT-I7 receives US FDA Orphan Drug Designation
Allergy Therapeutics reports positive interim results for G306 Phase III trial
Amytrx Therapeutics names new directors
Inimmune signs research collaboration with Boston Children's Hospital
ResVita Bio receives USD250,000 phase one Small Business Innovation Research grant from NIAID